Study identifier:D9676C00002
ClinicalTrials.gov identifier:NCT04989816
EudraCT identifier:N/A
CTIS identifier:N/A
A Single-arm Study of Trastuzumab Deruxtecan (T-DXd) Monotherapy for Patients with HER2-expressing Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Who Have Received 2 or More Prior Regimens (DESTINY-Gastric06)
Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Phase 2
No
Trastuzumab Deruxtecan
All
95
Interventional
18 Years - n/a
Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Jun 2024 by AstraZeneca
AstraZeneca
Daiichi Sankyo Co., Ltd.
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: T-DXd arm T-DXd monotherapy | - |